VCEL icon

Vericel Corp

38.02 USD
-1.34
3.40%
At close Apr 30, 4:00 PM EDT
After hours
38.02
+0.00
0.00%
1 day
-3.40%
5 days
-5.40%
1 month
-14.79%
3 months
-35.83%
6 months
-16.51%
Year to date
-31.01%
1 year
-17.11%
5 years
162.21%
10 years
1,345.63%
 

About: Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Employees: 357

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]

50% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 30

33% more capital invested

Capital invested by funds: $2.15B [Q3] → $2.86B (+$715M) [Q4]

23% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 82

4% more funds holding

Funds holding: 264 [Q3] → 274 (+10) [Q4]

2.8% more ownership

Funds ownership: 104.48% [Q3] → 107.28% (+2.8%) [Q4]

16% less call options, than puts

Call options by funds: $6.28M | Put options by funds: $7.49M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$51
34%
upside
Avg. target
$59
56%
upside
High target
$67
76%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Truist Securities
Richard Newitter
57% 1-year accuracy
29 / 51 met price target
34%upside
$51
Buy
Maintained
11 Apr 2025
HC Wainwright & Co.
Swayampakula Ramakanth
30% 1-year accuracy
57 / 190 met price target
58%upside
$60
Buy
Reiterated
28 Feb 2025
Canaccord Genuity
Caitlin Cronin
21% 1-year accuracy
3 / 14 met price target
76%upside
$67
Buy
Maintained
3 Feb 2025

Financial journalist opinion

Neutral
GlobeNewsWire
6 days ago
Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
Positive
Seeking Alpha
1 month ago
Vericel: Scalable Growth With Strong Margins
Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations.
Vericel: Scalable Growth With Strong Margins
Neutral
GlobeNewsWire
1 month ago
Vericel to Present at Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences:
Vericel to Present at Multiple Upcoming Investor Conferences
Neutral
Seeking Alpha
2 months ago
Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript
Vericel Corporation (NASDAQ:VCEL ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Felipe Lamar - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Genuity Mason Carrico - Stephens, Inc. Jeffrey Cohen - Ladenburg Thalmann & Co. Swayampakula Ramakanth - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript
Positive
Zacks Investment Research
2 months ago
Vericel Corporation (VCEL) Tops Q4 Earnings Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.26 per share a year ago.
Vericel Corporation (VCEL) Tops Q4 Earnings Estimates
Neutral
GlobeNewsWire
2 months ago
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22%
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
Neutral
GlobeNewsWire
2 months ago
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2024 financial results on Thursday, February 27, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
Positive
Investors Business Daily
2 months ago
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.
Positive
Zacks Investment Research
2 months ago
Vericel (VCEL) Is a Great Choice for 'Trend' Investors, Here's Why
Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Vericel (VCEL) Is a Great Choice for 'Trend' Investors, Here's Why
Negative
Benzinga
3 months ago
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday.
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Charts implemented using Lightweight Charts™